Vildagliptin: the known and unknown

Abstract

Vildagliptin is an innovative, effective DPP-4 inhibitor to be used as mono- or combination therapy of type 2 diabetes. The drug consistently reduces the level of glycated hemoglobin and does not increase the risk of hypoglycemia and cardiovascular disease. Numerous clinical studies have demonstrated the efficacy and safety of vildagliptin and opened new prospects for its application.

Keywords

• вилдаглиптин
• ингибиторы дпп-4
• сахарный диабет 2-го типа
• безопасность
• vildagliptin
• dpp-4 inhibitors
• type 2 diabetes
• safety